Arrowstreet Capital
MRVI icon

Arrowstreet Capital’s Maravai LifeSciences MRVI Stock Holding History

Arrowstreet Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.44M Buy
+1,513,606
New +$6.53M ﹤0.01% 1092
2022
Q1 		– Sell
-357,781
Closed -$15M – 1425
2021
Q4 		$15M Buy
357,781
+134,137
+60% +$5.43M 0.02% 547
2021
Q3 		$11M Buy
+223,644
New +$10.9M 0.01% 716

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Arrowstreet Capital's MRVI Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Maravai LifeSciences (MRVI) in Q2 2026: 1,513,606 shares worth $9.44M. The stake represents ﹤0.01% of the portfolio and ranks #1092 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in MRVI as recently as Q4 2021.

Arrowstreet Capital first reported a position in MRVI in Q3 2021 and has held it in 3 quarters since. The position peaked at $15M in Q4 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Arrowstreet Capital held 1,513,606 shares of Maravai LifeSciences worth $9.44M as of Q2 2026.
  • Maravai LifeSciences was a new Arrowstreet Capital position in Q2 2026.
  • Maravai LifeSciences made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1092 holding.
  • Arrowstreet Capital first reported a position in Maravai LifeSciences in Q3 2021 and has held it in 3 quarters since.
  • Arrowstreet Capital's Maravai LifeSciences position peaked at $15M in Q4 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.